Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 41 to 50 of 545 total matches.
Glucagon Nasal Powder (Baqsimi) for Severe Hypoglycemia
The Medical Letter on Drugs and Therapeutics • Sep 23, 2019 (Issue 1581)
see' mee
SEVERE HYPOGLYCEMIA – Hypoglycemia is
classified as level 1 (blood glucose ≥54 and ...
The FDA has approved glucagon nasal powder
(Baqsimi – Lilly) for treatment of severe hypoglycemia
in patients ≥4 years old with diabetes. Baqsimi is the
first noninjectable glucagon formulation to become
available in the US. Injectable glucagon emergency kits
(GlucaGen Hypokit, and generic) have been available
for years, but they require reconstitution of the
lyophilized powder by the caregiver immediately before
injection. An injectable glucagon formulation that does
not require reconstitution was recently approved by the
FDA (Gvoke) and is expected to become available...
Cetirizine Ophthalmic Solution (Zerviate) for Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • Jun 01, 2020 (Issue 1599)
compresses, and avoidance of eye rubbing and contact
lens wearing during symptomatic periods.1
Many ...
A 0.24% ophthalmic solution of the second-generation
H1-antihistamine cetirizine (Zerviate – Eyevance) is now
available by prescription for treatment of ocular itching
associated with allergic conjunctivitis in patients ≥2
years old. Oral cetirizine (Zyrtec, and others), which is
used for treatment of allergic conjunctivitis and rhinitis,
has been available over the counter (OTC) for years.
Tapinarof Cream (Vtama) for Psoriasis
The Medical Letter on Drugs and Therapeutics • Aug 08, 2022 (Issue 1656)
' uh
The FDA has approved Vtama (Dermavant), a 1%
cream formulation of the aryl hydrocarbon receptor ...
The FDA has approved Vtama (Dermavant), a 1%
cream formulation of the aryl hydrocarbon receptor
(AhR) agonist tapinarof, for treatment of adults with
plaque psoriasis. It is the first AhR agonist to be
approved by the FDA.
A Three-Antigen Hepatitis B Vaccine (PreHevbrio)
The Medical Letter on Drugs and Therapeutics • May 16, 2022 (Issue 1650)
hepatitis B vaccination rate among
adults was 30%.1
NEW RECOMMENDATIONS — The Advisory Committee ...
The FDA has licensed PreHevbrio (VBI Vaccines), a
recombinant, 3-antigen, 3-dose hepatitis B vaccine,
for the prevention of infection caused by all known
subtypes of hepatitis B virus (HBV) in adults. It has
been available in Israel since 2000.
Comparison Table: Some Nasal Sprays for Allergic Rhinitis (online only)
The Medical Letter on Drugs and Therapeutics • Apr 19, 2021 (Issue 1622)
Usual Dosage Comments Class Comments Cost1
H1-Antihistamines
Azelastine 0.1%–
generic
Azelastine ...
View the Comparison Table: Some Nasal Sprays for Allergic Rhinitis
In Brief: Shingrix for Immunocompromised Adults
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021 (Issue 1631)
or immunosuppression.
Shingrix has been licensed for herpes
zoster prevention in adults ≥50 years old since 2017.1 ...
The FDA has licensed the adjuvanted, recombinant
varicella zoster virus (VZV) vaccine Shingrix (GSK) for
prevention of herpes zoster (shingles) in adults of any
age who are or will be at elevated risk because of disease-
or therapy-induced immunodeficiency or immunosuppression.
Shingrix has been licensed for herpes
zoster prevention in adults ≥50 years old since 2017.1
It is the only VZV vaccine currently available in the US;
Zostavax, a live-attenuated VZV vaccine, was withdrawn
from the market in 2020.
Rilonacept (Arcalyst) for Recurrent Pericarditis
The Medical Letter on Drugs and Therapeutics • Sep 06, 2021 (Issue 1632)
Rilonacept (Arcalyst) for Recurrent Pericarditis
Rilonacept (Arcalyst – Kiniksa), an interleukin-1 ...
Rilonacept (Arcalyst – Kiniksa), an interleukin-1 (IL-1)
antagonist that has been available for years for
treatment of cryopyrin-associated periodic syndromes,
has now been approved by the FDA for treatment
of recurrent pericarditis and prevention of further
recurrences in patients ≥12 years old. It is the first drug
to be approved in the US for this indication. Anakinra
(Kineret), an IL-1 receptor antagonist FDA-approved for
treatment of rheumatoid arthritis, has been used off-label
for years for treatment of recurrent pericarditis.
Nalmefene Returns for Reversal of Opioid Overdose
The Medical Letter on Drugs and Therapeutics • Sep 05, 2022 (Issue 1658)
Nalmefene Returns for Reversal of Opioid Overdose
Table 1. Pharmacology of Nalmefene
Class Opioid ...
The FDA has approved a generic injectable formulation
of the opioid antagonist nalmefene (Purdue) for the
management of known or suspected opioid overdose.
Revex, the reference product, was withdrawn from the
market in 2008 for commercial reasons.
An EUA for Sotrovimab for Treatment of COVID-19
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021 (Issue 1627)
of progressing to severe disease, including
hospitalization and death.1
Two other monoclonal
antibody ...
The investigational monoclonal antibody sotrovimab
(VIR-7831; GSK/Vir Biotechnology) has been granted
an FDA Emergency Use Authorization (EUA) for
treatment of mild to moderate COVID-19 in patients
≥12 years old who weigh ≥40 kg and are at high
risk of progressing to severe disease, including
hospitalization and death.1 Two other monoclonal
antibody regimens are authorized for the same
indication: casirivimab (REGN10933) and imdevimab
(REGN10987) administered together, and bamlanivimab (LY-CoV555) and etesevimab (LYCoV016)
administered together.
The FDA revoked its EUA...
Emicizumab (Hemlibra) for Subcutaneous Prophylaxis in Hemophilia A
The Medical Letter on Drugs and Therapeutics • May 20, 2019 (Issue 1572)
-linked
recessive deficiency of coagulation factor VIII that
occurs in about 1 in 5000 male births ...
The FDA has approved emicizumab-kxwh (Hemlibra –
Genentech), a subcutaneously injected, factor IXa- and
X-directed antibody, for routine prophylaxis to
prevent or reduce bleeding episodes in patients with
hemophilia A. Emicizumab is not recommended for
treatment of bleeding.